Genentech have announced positive results from a phase III study of ocrelizumab in primary progressive MS
Source Pharmiweb.com
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from a pivotal Phase III study that evaluated the investigational medicine ocrelizumab in people with primary progressive multiple sclerosis (PPMS). Read on.